Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

Autor: Agnes Nagy, Rene-Olivier Casasnovas, Sameer Bakhshi, Sharon Shacham, Juan-Manuel Sancho, Ronit Gurion, Josée M. Zijlstra, Jatin P. Shah, Miklos Egyed, Brian T. Hill, Krzysztof Warzocha, Gabriel Tremblay, Michael W. Schuster, Fritz Offner, Reda Bouabdallah, Dimitrios Tomaras, Paolo Caimi, Andre Goy, Priyanka Samal, Catherine Thieblemont, Joost S.P. Vermaat, Matthew Ku, Ulrich Jäger, John Kuruvilla, Nagesh Kalakonda, George A Follows, Eric Van Den Neste, Miguel Ángel Canales Albendea, Michael Kauffman, Nada Hamad, Fatima De la Cruz, Patrick Daniele, Marie Maerevoet, Theodoros Vasilakopoulos, Federica Cavallo, Sylvain Choquet

Publikováno v: Future Oncology
Future Oncology, Future Medicine, 2021, 17 (11), pp.1295-1310. ⟨10.2217/fon-2020-0946⟩
Future Oncology, 17(11), 1295-1310. FUTURE MEDICINE LTD
FUTURE ONCOLOGY
Future oncology, Vol. 17, no.11, p. 1295-1310 (2021)

Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6489da8e0ec446342a61908102b6dd3
https://doi.org/10.2217/fon-2020-0946

Managing the front‐line treatment for diffuse large B cell lymphoma and high‐grade B cell lymphoma during the COVID‐19 outbreak

Autor: Abel Dos Santos-Ortas, Ana López de la Guía, Víctor Jiménez-Yuste, Miguel Ángel Canales-Albendea, Teresa de Soto-Álvarez, Andrés Ramírez-López, Irene Sánchez-Vadillo, Gema Casado-Abad, Paula Lázaro del Campo, Karem Humala-Barbier, Eduardo García-Pérez, Beatriz de la Cruz-Benito

Publikováno v: British Journal of Haematology

The COVID‐19 pandemic has dramatically challenged care for cancer patients, especially those with active treatment that represent a vulnerable population for SARS‐CoV‐2 infection. Aggressive lymphoid neoplasms, such as diffuse large B‐cell ly

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9774147e90617d045b418e346b5b55bd
https://doi.org/10.1111/bjh.17066

Responsabilidad social empresarial como productora de ventajas competitivas

Autor: Miguel Ángel Canales-Rodríguez, Hirana Gutiérrez-Kurumilla, Cesar Sánchez-Ocampo

Publikováno v: Revista de Aplicaciones del Derecho. :7-20

Currently, a new company is claimed that includes the principles of sustainability and results in its actions, generating satisfaction for all stakeholders. Corporate social responsibility (CSR) seeks to create a balance between economic benefits and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4a16eeab7f3309c453bc32fedfbda093
https://doi.org/10.35429/10.35429/jla.2019.10.3.7.20

Obinutuzumab short-duration infusion (SDI) in previously untreated advanced follicular lymphoma: Results from the end of induction analysis of the phase IV GAZELLE study

Autor: Sunny Pokala, Ekaterina Vorozheikina, Thomas A. Buchholz, Laura Fogliatto, Dirk Klingbiel, Takayuki Ishikawa, Monique S Tomiczek, Joana Parreira, Kai Hübel, Miguel Ángel Canales Albendea, Koji Izutsu

Publikováno v: Journal of Clinical Oncology. 39:7545-7545

7545 Background: Obinutuzumab (G)-chemotherapy (chemo) has demonstrated improved progression-free survival compared with rituximab (R)-chemo in previously untreated advanced follicular lymphoma (FL). G is currently administered by IV infusion over ̃

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f5ba9e3f07a943f5ee438764c265dee4
https://doi.org/10.1200/jco.2021.39.15_suppl.7545

Impacto clínico de la cuantificación de la carga mutacional de JAK2V617F en pacientes con neoplasias mieloproliferativas crónicas Ph negativas clásicas

Autor: Miguel Ángel Canales Albendea, Luis Lombardia, Ana Esther Kerguelen Fuentes, Ana Rodríguez de la Rúa, Dolores Hernández-Maraver

Publikováno v: Medicina Clínica. 139:373-378

Resumen Fundamento y objetivo La identificacion de la mutacion V617F del gen JAK2 en pacientes diagnosticados de neoplasias mieloproliferativas cronicas (NMPC) es fundamental en el cribado diagnostico. Nuestro objetivo fue investigar la asociacion en

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::aee99fd59470eaf9470f66410c73019d
https://doi.org/10.1016/j.medcli.2012.03.032